1. Lena Eliasson  Is a corresponding author
  2. Anna Wendt
  1. Lund University, Sweden

Diabetes is a disease that causes the level of glucose in the blood to become too high. In healthy individuals, two hormones – called insulin and glucagon – work together to keep blood glucose levels within strict limits. Insulin is released when the level of glucose becomes too high, and it stimulates the removal of glucose from the blood so that it can be stored in tissues. On the other hand, glucagon is released when the level of glucose becomes too low, and it triggers the release of glucose from the tissues into the bloodstream.

Many diabetic patients are not able to produce insulin and rely on regular insulin injections to prevent their blood glucose from reaching dangerous levels (insulin-dependent diabetes). Although these injections save lives, they are not sufficient to achieve and maintain the levels of blood glucose that are found in healthy individuals. Even patients considered to have well-controlled diabetes suffer from complications that can damage many tissues in the body. The fact that diabetic patients have too little insulin, as well as uncontrolled levels of glucagon, has led to the hypothesis that diabetes is triggered by inappropriate levels of both hormones, not just insulin alone (Unger and Orci, 1975).

Both insulin and glucagon are produced in the pancreas, within structures called the Islets of Langerhans. Destroying the cells that produce insulin – known as β-cells – causes normal mice to develop diabetes. However, several researchers have recently reported that mice lacking the receptor for glucagon do not develop diabetes when their β-cells are destroyed (Conarello et al., 2007; Lee et al., 2011). These data have attracted a lot of attention since they hold the promise of a new way to treat diabetes, but the conclusions are disputed (Steenberg et al., 2016). Now, in eLife, Pedro Herrera from the University of Geneva and co-workers – including Nicolas Damond as first author – report that inhibiting the action of glucagon to treat diabetes only works if a certain number of β-cells are still present (Damond et al., 2016).

Damond et al. – who are based at the University of Geneva, Eli Lilly, Albert Einstein College of Medicine, Columbia University and Vanderbilt University – made use of mice lacking the glucagon receptor and, in separate experiments, antibodies that can block glucagon signaling. Using these two strategies they were able to elegantly show that if virtually all the β-cells were destroyed, blocking the glucagon signal could not prevent diabetes. However, when the majority, but not all, of the β-cells are destroyed, blocking the glucagon signal could prevent the mice from developing diabetes.

These findings naturally raise the question of whether it is possible to treat diabetes by replacing some of the lost β-cells and administering glucagon inhibitors, instead of giving insulin injections. When faced with severe β-cell loss, the α-cells that normally only produce glucagon can convert to producing both insulin and glucagon (Thorel et al., 2010). Earlier studies show that blocking the glucagon signal increases the number of α-cells (Gelling et al., 2003). Here, Damond et al. show that α-cells are still able to convert to produce both hormones when the glucagon signal is blocked, which results in the Islet of Langerhans having a higher absolute number of α-cells that produce both insulin and glucagon.

How do these findings apply to humans? The experiments make it clear that diabetic patients who cannot produce any insulin would not benefit from a blockade of glucagon signaling. Damond et al. also alert us to the fact that a combination of insulin treatment and blockage of glucagon action might be risky. According to experiments in their laboratories, glucagon signaling is vital to reduce the risk of blood glucose levels becoming too low after insulin injections (unpublished data).

On the other hand, if a patient has enough β-cells to be able to properly respond to changes in blood glucose levels, blocking the glucagon signal might be a useful treatment strategy. Many diabetic patients are not dependent on insulin injections because their β-cells are able to produce some insulin, but not enough to meet the demand. Changes in lifestyle and diet are often effective ways to reduce symptoms in these patients, but it is possible that they could also benefit from receiving drugs that block the glucagon signal.

We know that some patients with insulin-dependent diabetes still have some functional β-cells (Ludvigsson and Heding, 1976). It is not yet clear how many β-cells would be needed for glucagon signal blockers to be an effective alternative to insulin treatment. However, recent advances in understanding how to maintain and/or increase insulin production (Carlsson et al., 2015) provide us with confidence that this milestone will eventually be reached. Although it is not clear what the ideal balance of α-cells and β-cells in the Islets of Langerhans is, the work of Damond et al. tells us that optimal control of blood glucose levels requires these cells to be partners for life.


Article and author information

Author details

  1. Lena Eliasson

    Unit of Islet Cell Exocytosis, Lund University Diabetes Centre, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden
    For correspondence
    Competing interests
    The authors declare that no competing interests exist.
  2. Anna Wendt

    Unit of Islet Cell Exocytosis, Lund University Diabetes Centre, Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8807-5979

Publication history

  1. Version of Record published: May 18, 2016 (version 1)


© 2016, Eliasson et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.


  • 783
    Page views
  • 109
  • 1

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Lena Eliasson
  2. Anna Wendt
Diabetes: Partners for life
eLife 5:e16798.
  1. Further reading

Further reading

    1. Biochemistry and Chemical Biology
    Meiling Wu, Anda Zhao ... Dongyun Shi
    Research Article

    Antioxidant intervention is considered to inhibit reactive oxygen species (ROS) and alleviates hyperglycemia. Paradoxically, moderate exercise can produce ROS to improve diabetes. The exact redox mechanism of these two different approaches remains largely unclear. Here, by comparing exercise and antioxidants intervention on type 2 diabetic rats, we found moderate exercise upregulated compensatory antioxidant capability and reached a higher level of redox balance in the liver. In contrast, antioxidant intervention achieved a low-level redox balance by inhibiting oxidative stress. Both of these two interventions could promote glucose catabolism and inhibit gluconeogenesis through activation of hepatic AMPK signaling, therefore ameliorating diabetes. During exercise, different levels of ROS generated by exercise have differential regulations on the activity and expression of hepatic AMPK. Moderate exercise-derived ROS promoted hepatic AMPK glutathionylation activation. However, excessive exercise increased oxidative damage and inhibited the activity and expression of AMPK. Overall, our results illustrate that both exercise and antioxidant intervention improve blood glucose in diabetes by promoting redox balance, despite different levels of redox balance. These results indicate that the AMPK signaling activation, combined with oxidative damage markers, could act as a sensitive biomarker, reflecting the threshold of redox balance defining effective treatment in diabetes. These findings provide theoretical evidence for the precise treatment of diabetes by antioxidants and exercise.

    1. Biochemistry and Chemical Biology
    2. Cell Biology
    Edmundo G Vides, Ayan Adhikari ... Suzanne R Pfeffer
    Research Advance

    Activating mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) cause Parkinson's disease and previously we showed that activated LRRK2 phosphorylates a subset of Rab GTPases (Steger et al., 2017). Moreover, Golgi-associated Rab29 can recruit LRRK2 to the surface of the Golgi and activate it there for both auto- and Rab substrate phosphorylation. Here we define the precise Rab29 binding region of the LRRK2 Armadillo domain between residues 360-450 and show that this domain, termed 'Site #1', can also bind additional LRRK2 substrates, Rab8A and Rab10. Moreover, we identify a distinct, N-terminal, higher affinity interaction interface between LRRK2 phosphorylated Rab8 and Rab10 termed 'Site #2', that can retain LRRK2 on membranes in cells to catalyze multiple, subsequent phosphorylation events. Kinase inhibitor washout experiments demonstrate that rapid recovery of kinase activity in cells depends on the ability of LRRK2 to associate with phosphorylated Rab proteins, and phosphorylated Rab8A stimulates LRRK2 phosphorylation of Rab10 in vitro. Reconstitution of purified LRRK2 recruitment onto planar lipid bilayers decorated with Rab10 protein demonstrates cooperative association of only active LRRK2 with phospho-Rab10-containing membrane surfaces. These experiments reveal a feed-forward pathway that provides spatial control and membrane activation of LRRK2 kinase activity.